CYP2E1 and NQO1 genotypes, smoking and bladder cancer

Pharmacogenetics

Volumn 13, Issue 6, 2003, Pages 349-355

  Choi, Ji Yeob ^a   Lee, Kyoung Mu ^a   Cho, Soo Hun ^a   Kim, Soo Woong ^a   Choi, Han Yong ^b   Lee, Sang Yoon ^a   Im, Hyoung June ^a   Yoon, Ki Jung ^a   Choi, Hwang ^a   Choi, Inmi ^a   Hirvonen, Ari ^c   Hayes, Richard B ^d   Kang, Daehee ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bladder cancer; Combined effect; CYP2E1; Genetic polymorphisms; NQO1

Indexed keywords

CYTOCHROME P450 2E1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE);

ADULT; AGED; ARTICLE; ASIA; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA FLANKING REGION; EXON; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HISTOPATHOLOGY; HOSPITAL; HUMAN; HUMAN TISSUE; KOREA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SMOKING HABIT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2E1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; NAD(P)H DEHYDROGENASE (QUINONE); SMOKING; URINARY BLADDER NEOPLASMS;

NICOTIANA TABACUM;

EID: 12444302843     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200306000-00006     Document Type: Article

References (45)

1. Silverman DT, Rothman N, Devesa SS. Epidemiology of bladder cancer. In: Syrigos KN and Skinner DG, eds. Bladder cancer; biology, diagnosis and management. New York: Oxford University Press; 1999:11-55.
2. Negri E, La Vecchia C. Epidemiology and prevention of bladder cancer. Eur J Cancer Prev 2001; 10:7-14.
3. Lee CW, Lee ES, Choi H, Koh SK, Lee JM, Chai SE, et al. Incidence estimation of genitourinary cancer in Korea. J Korean Med Sci 1992; 7(2):154-161.
4. Vineis P, Simonato L. Proportion of lung and bladder cancers in males resulting from occupation: a systematic approach. Arch Environ Health 1991; 46:6-15.
5. Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992; 13:1789-1794.
6. Okada M, Ishidate M. Metabolic fate of N-n-butyl-N-(4-hydroxybutyl)-nitrosamine and its analogues. Selective induction of urinary bladder tumours in the rat. Xenobiotica 1997; 7:11-24.
7. Tan W, Song N, Wang GQ, Liu Q, Tang HJ, Kadlubar FF, et al. Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferase M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiol Biomarker Prev 2000; 9:551-556.
8. Le Marchand L, Wilkinson GR, Wilkens LR. Genetic and dietary predictors of CYP2E1 activity: A phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarker Prev 1999; 8:495-500.
9. Kim RB, Yamazaki H, Chiba K, O'Shea D, Mimura M, Guengerich FP, et al. In vivo and vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther 1996; 276:4-11.
10. Brockmöller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferase M1, and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996; 56:3915-3925.
11. Anwar WA, Abdel-Rahman SZ, El-Zein RA, Mostafa HM, Au WW. Genetic polymorphism of GSTM1, CYP2E1, and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 1996; 17:1923-1929.
12. Farker K, Lehmann MH, Oelschlagel B, Haerting J, Hoffmann A, Janitzky V, et al. Impact of CYP2E1 genotype in renal cell and urothelial cancer patients. Exp Toxic Pathol 1998; 50:425-431.
13. Kato S, Sheilds PG, Caporaso NE, Hoover RN, Trump BF, Sugimura H, et al. Cytochrome P450IIE1 genetic porymorphisms, racial variation, and lung cancer risk. Cancer Res 1992; 52:6712-6715.
14. Cadenas E. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem Pharmacol 1995; 49:127-140.
15. Chen S, Knox R, Lewis AD, Friedlos F, Workman P, Deng PSK, et al. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes. Mol Pharmacol 1995; 47:934-939.
16. Cenas N, Nemeikaitè A, Dičkancaitč E, Anusevičius Z, Nivinskas H, Bironaitč D. The toxicity of aromatic nitrocompounds to bovine leukemia virus-transformed fibroblasts: the role of single-electron reduction. Biochem Biophys Acta 1995; 1268:159-164.
17. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer THW, Danenberg PV, Ross D, et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992; 52:797-802.
18. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinine oxidoreductase 1. Pharmacogenetics 1999; 9:113-121.
19. Wiencke JK, Spitz MR, McMillan A, Kelsey KT. Lung Cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarker Prev 1997; 6:87-92.
20. 609C→T polymorphism with a decreased lung cancer risk. Cancer Res 1999; 59:3045-3048.
21. Sunaga N, Kohno T, Yanagitani N, Sugimura H, Kunitoh H, Tamura T, et al. Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. Cancer Epidemiol Biomarker Prev 2002; 11:730-738.
22. Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, Kato T, et al. NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 2002; 7:103-18.
23. Lewis SJ, Cherry NM, Niven RM, Barber PV, Povey AC. Polymorphisms in the NAD(P)H:quinone oxidoreductase gone and small cell lung cancer risk in a UK population. Lung Cancer 2001; 34:177-183.
24. Xu LL, Wain JC, Miller DP, Thurston SW, Su L, Lynch TJ, et al. The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarker Prev 2001; 10:303-309.
25. Schulz WA, Krummeck A, Rösinger I, Eickelmann P, Neuhaus C, Ebert T, et al. Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 1997; 7:235-239.
26. 609 C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999; 94:803-807.
27. Lee SJ, Cho SH, Park SK, Kim SW, Park MS, Chou HY, et al. Combined effect of glutathione S-transferase M1 and T1 genotypes on bladder cancer risk. Cancer Lett 2002; 177:173-179.
28. Silverman DT, Levin LL, Hoover RN, Hartge P. Occupational risks of bladder cancer in the United States: I. White men. J Natl Cancer Inst 1989; 81:1472-1480.
29. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. IARC Scientific Publications No. 32; 1980.
30. Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, et al. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 1998; 58:3603-3610.
31. Taioli E, Zocchetti C, Garte S. Models of interaction between metabolic genes and environmental exposure in cancer susceptibility. Environ Health Perspect 1998; 106:67-70.
32. Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, et al. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 2001; 166:171-177.
33. Nishimoto IN, Hanaoka T, Sugimura H, Nagura K, Ihara M, Li XJ, et al. Cytochrome P450 2E1 polymorphism in gastric cancer in Brazil: case-control studies of Japanese Brazilians and Non-Japanese Brazilians. Cancer Epidemiol Biomark Prev 2000; 9:675-680.
34. Wu X, Shi H, Jiang H, Kemp B, Hong WK, Delclos G, et al. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis 1997; 18:967-973.
35. Liu S, Park JY, Schantz SP, Stern JC, Lazarus P. Elucidation of CYP2E1 5′ regulatory RsallPstl allelic variants and their role in risk for oral cancer. Oral Oncol 2001; 37:437-445.
36. Lin P, Wang HJ, Lee H. NAD(P)H:quinone oxidoreductase polymorphism and lung cancer in Taiwan. J Toxicol Environ Health, Part A 1999; 58:187-197.
37. Peluso M, Airoldi L, Magagnotti C, Fiorini L, Munnia A, Hautefeuiile A, et al. White blood cell DNA adducts and fruit and vegetable consumption in bladder cancer. Carcinogenesis 2000; 21:183-187.
38. Kelsey KT, Ross D, Traver RD, Christiani DC, Zuo Z-F, Spitz MR, et al. Ethnic variation in the prevalence of a common NAD(P)H quinine oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 1997; 76:852-854.
39. Airoldi L, Magagnotti C, Bonfanti M, Fanelli R. Alpha-oxidative metabolism of the bladder carcinogens N-nitrosobutyl (4-hydroxybutyl) amine and N-nitrosobutyl (3-carboxypropyl) amine within the rat isolated bladder. Carcinogenesis 1990; 11:1437-1440.
40. Janzowski C, Landsiedel R, Golzer P, Eisenbrand G. Mitochondrial formation of β-oxopropyl metabolites from bladder carcinogenic ω-carboxyalkylnitrosamine. Chem-Biol Interact 1994; 90:23-33.
41. Yamashita M, Wakabayashi K, Nagao M, Sato S, Yamaizumi Z, Takahashi M, et al. Detection of 2-amino-3-methylimidazo [4,5-f] quinoline in cigarette smoke condensate. Jpn J Cancer Res 1986; 77:419-422.
42. Manabe S, Wada O. Carcinogenic tryptophan pyrolysis products in the environment. J Toxicol Sci 1991; 16(suppl 1):63-72.
43. De Flora S, Bennicelli C, D'Agostini F, Izzotti A, Camoirano A. Cytosolic activation of aromatic and heterocyclic amines: inhibition by dicoumarol and enhancement in viral hepatitis B. Environ Health Perspect 1994; 102(suppl 6):69-74.
44. Bergamaschi E, De Palma GD, Mozzoni P, Vanni S, Vettori MV, Broeckaert F, et al. Polymorphism of quinone-metabolizing enzymes and susceptibility to ozone-induced acute effects. Am J Respir Crit Care Med 2001; 163:1426-1431.
45. Choudry GA, Hamilton Stewart PA, Double JA, Krul MRL, Naylor B, Flannigan GM, et al. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of E09. Br J Cancer 2001; 85:1137-1146.